You are here

Sanofi

Rilzabrutinib granted FDA fast track designation for treatment of immune thrombocytopenia

Rilzabrutinib granted FDA fast track designation for treatment of immune thrombocytopenia

Pharmaceutical Business Review

Principia Biopharma

chronic immune thrombocytopenia

Flag link:

FDA to expedite development of two Sanofi rare disease drugs

FDA to expedite development of two Sanofi rare disease drugs

Pharmaforum

Avalglucosidase alfa

Flag link:

Sanofi grapples with rejection of potential first-in-class orphan drug, faults third-party manufacturing

Sanofi grapples with rejection of potential first-in-class orphan drug, faults third-party manufacturing

Endpoints

drug manufacturing

Flag link:

France’s Medicine Watchdog Indicted Over Sanofi’s Birth Defect-Causing Drug

France’s Medicine Watchdog Indicted Over Sanofi’s Birth Defect-Causing Drug

BioSpace

Flag link:

Doubling down on Sanofi's French roots, Paul Hudson infuses €50M into Jeito Capital to boost homegrown biotechs

Doubling down on Sanofi's French roots, Paul Hudson infuses €50M into Jeito Capital to boost homegrown biotechs

Endpoints

Flag link:

Pfizer's COVID-19 vaccine looks impressive, but Sanofi, J&J and Novavax shots eye a logistics edge

Pfizer's COVID-19 vaccine looks impressive, but Sanofi, J&J and Novavax shots eye a logistics edge

Fierce Pharma

Flag link:

Sanofi/Alnylam’s haemophilia drug hits another safety speed-bump

Sanofi/Alnylam’s haemophilia drug hits another safety speed-bump

Pharmaforum

Flag link:

Sanofi inks $358M Kiadis takeover to acquire NK-cell platform

Sanofi inks $358M Kiadis takeover to acquire NK-cell platform

Fierce Biotech

natural killer cell therapy

Flag link:

Go or no go? Big decisions loom for Bristol and Sanofi

Go or no go? Big decisions loom for Bristol and Sanofi

EP Vantage

Bristol-Myers Squibb

Flag link:

Sanofi, despite COVID-19, sees early gains from CEO Hudson's strategy revamp

Sanofi, despite COVID-19, sees early gains from CEO Hudson's strategy revamp

Fierce Pharma

Flag link:

Watch out, Merck: FDA grants Regeneron, Sanofi's Libtayo priority review for coveted first-line use in lung cancer

Watch out, Merck: FDA grants Regeneron, Sanofi's Libtayo priority review for coveted first-line use in lung cancer

Fierce Pharma

priority review

non-small cell lung cancer

Flag link:

Sanofi to Evaluate THOR-707 with Merck's Checkpoint Inhibitor Keytruda

Sanofi to Evaluate THOR-707 with Merck's Checkpoint Inhibitor Keytruda

BioSpace

Flag link:

Sanofi, GSK pledge 200M doses to an international coronavirus vaccine alliance

Sanofi, GSK pledge 200M doses to an international coronavirus vaccine alliance

BioPharma Dive

Flag link:

Sanofi, Regeneron chase 4th Dupixent approval with rare esophageal disease data

Sanofi, Regeneron chase 4th Dupixent approval with rare esophageal disease data

Fierce Pharma

eosinophilic esophagitis

Flag link:

Sanofi, intent on slimming down, mulls $200M-plus sale of anti-inflammation meds: report

Sanofi, intent on slimming down, mulls $200M-plus sale of anti-inflammation meds: report

Fierce Pharma

Flag link:

COVID-19 mRNA vaccine candidate from Sanofi and Translate protects mice, monkeys: study

COVID-19 mRNA vaccine candidate from Sanofi and Translate protects mice, monkeys: study

Fierce Biotech

Flag link:

Dupixent Posts Positive Results in Phase III Pediatric Asthma Study

Dupixent Posts Positive Results in Phase III Pediatric Asthma Study

BioSpace

clinical trials

Flag link:

Gilead rescues biopharma’s takeout scene

Gilead rescues biopharma’s takeout scene

EP Vantage

Gilead Sciences

Momenta Pharmaceuticals

Principia Biopharma

Tizona Therapeutics

Flag link:

Drugmakers push forward on large-scale production of coronavirus vaccines

Drugmakers push forward on large-scale production of coronavirus vaccines

BioPharma Dive

Operation Warp Speed

Moderna Therapeutics

Flag link:

Here come the tortoises: In the race for a Covid-19 vaccine, slow starters could still win out

Here come the tortoises: In the race for a Covid-19 vaccine, slow starters could still win out

Stat

Moderna Therapeutics

Flag link:

Pages